Week Ending April 5, 2021

Pfizer’s Vizimpro is among 3 FDA-approved drugs that combat COVID-19 in lung cells: report
“Ever since the COVID-19 pandemic was declared over a year ago, researchers around the world have been searching for existing drugs that might be repurposed to fight the virus. A team led by the University of Pennsylvania is adding three candidates to the growing list of potential anti-COVID-19 candidates—medicines they believe are particularly promising because they appear to inhibit the virus in respiratory cells.”

The states and counties with the highest rates of lung cancer
“Despite concerted public health efforts in cancer prevention and new innovations in diagnosis and treatment over the years, cancer remains America’s second-leading cause of death after cardiovascular disease.”

Targeted cancer therapy linked with adverse ocular events
“Targeted cancer therapy (TCT) has the potential to cause ocular toxicity, early recognition of which may prevent irreversible damage to the eye.”

High Tumor Mutation Burden Predicts Response to Immune Checkpoint Blockade for Some Cancer Types
“A study investigating the predictive capabilities of high tumor mutation burden (TMB) found it was predictive of clinical responses to immune checkpoint inhibitors for a subset of cancer types, according to data published in Annals of Oncology.1”

7 Recent COVID-19 News and Updates That Patients With Cancer May Have Missed
“There has been countless news and updates involving COVID-19 during the past several months, including a third vaccine being granted emergency use authorization from the Food and Drug Administration (FDA). Here, CURE® looks back at some of the information regarding the virus and its connection to cancer that patients with cancer may have missed.”

What to know about treating NSCLC with checkpoint inhibitors
“Checkpoint inhibitors are a newer form of therapy that helps the body’s immune system target cancer cells.”

The Impact of Adjuvant Osimertinib in Resectable Non–Small Cell Lung Cancer
“Although early-stage non–small cell lung cancer (NSCLC) is potentially curable, patients with stage IB-IIIA NSCLC have a very high risk of recurrence and suboptimal survival.”

Higher-Dose Radiotherapy Improved Survival, Maintained Level of Toxicity for Limited-Stage SCLC
“Patients with limited-stage small cell lung cancer (LS-SCLC) experienced a substantial survival benefit without increased toxicity with a radiotherapy dose of 60 Gy compared with a lower dose of 45 Gy, according to data from a phase 2 trial (NCT02041845) published in The Lancet Oncology.”

Video:
Women’s Health: Advances in lung cancer treatment
“ALBANY, N.Y. (NEWS10) — Between 80% and 85% of all lung cancer cases are considered to be non-small cell cancer, according to Harvard Medical School. There is a new treatment on the horizon that could improve outcomes, as NEWS10’s Christina Arangio found out when she talked to Dr. Hossein Borghaei.”